Arcutis Biotherapeutics IncNASDAQ:ARQT
- LAST PRICE9.5600
- TODAY'S CHANGE (%)0.2600 (2.7957%)
- Bid / Lots9.5600/ 6
- Ask / Lots9.5900/ 10
- Open / Previous Close9.1900 / 9.3000
- Day Range
- 52 Week Range
- Volume151,801
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ARQT |
|---|---|---|
| 09:32 ET | 38606 | 9.21 |
| 09:34 ET | 4631 | 9.27 |
| 09:36 ET | 22748 | 9.41 |
| 09:38 ET | 16994 | 9.39 |
| 09:39 ET | 6710 | 9.47 |
| 09:41 ET | 32757 | 9.57 |
| 09:43 ET | 13415 | 9.56 |
Jun 10, 2024
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference, from 2:30PM ET on Monday Jun 10, 2024 by Dow Jones
2:30PM ET on Monday Jun 10, 2024 by Dow Jones
Jun 5, 2024
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:00PM ET on Wednesday Jun 05, 2024 by Dow Jones
4:00PM ET on Wednesday Jun 05, 2024 by Dow JonesPress Release: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:00PM ET on Wednesday Jun 05, 2024 by Dow Jones
4:00PM ET on Wednesday Jun 05, 2024 by Dow JonesArcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference, from 8:00AM ET on Wednesday Jun 05, 2024 by Dow Jones
8:00AM ET on Wednesday Jun 05, 2024 by Dow Jones
Jun 3, 2024
Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 8:00AM ET on Monday Jun 03, 2024 by Dow Jones
8:00AM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Arcutis Biotherapeutics Inc | 1.1B | -3.3x | --- |
Silence Therapeutics PLC | 886.5M | -16.7x | --- |
Immatics NV | 1.2B | -11.3x | --- |
Prothena Corporation PLC | 1.1B | -6.4x | --- |
4D Molecular Therapeutics Inc | 1.1B | -9.1x | --- |
CureVac NV | 762.6M | -2.7x | --- |
Company Information
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Contact Information
- Headquarters
- 3027 Townsgate Road, Suite 300WESTLAKE VILLAGE, CA, United States 91361
- Phone
- 805-418-5006
- Fax
- 302-531-3150
Executives
- Independent Chairman of the Board
- Patrick Heron
- President, Chief Executive Officer, Director
- Todd Watanabe
- Chief Financial Officer, Senior Vice President
- David Topper
- Senior Vice President, General Counsel
- Masaru Matsuda
- Senior Vice President, Chief Medical Officer
- Patrick Burnett
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
|---|---|
Revenue (TTM) | $106.4M |
Shares Outstanding | 115.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.18 |
EPS | $-2.91 |
Book Value | $0.92 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | 10.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -184.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
